ArticleTheranostics2021
Co-delivery of siPTPN13 and siNOX4
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Cellular Senescence: Emerging Therapeutic Target for Idiopathic Pulmonary Fibrosis Pathogenic Mechanisms and Therapeutic Strategies.Biomolecules & therapeutics · 2026Review
- Mesenchymal stem cell-derived extracellular vesicles attenuate liver transplantation-induced ischemia/reperfusion injury by suppressing hepatocellular complement C5 expression.Journal of nanobiotechnology · 2026Article
- Synergistic regulation of TGF-β1/Smad2/3 signaling and inflammatory pathways via SA/NAC-based nanoplatforms: a novel strategy to enhance anti-fibrotic therapeutic outcomes in idiopathic pulmonary fibrosis.Journal of nanobiotechnology · 2026Article
- Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities.International journal of nanomedicine · 2026Review
- Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution.Seminars in respiratory and critical care medicine · 2025Review
- Pulmonary fibrosis: from mechanisms to therapies.Journal of translational medicine · 2025Review
- Polymeric nanocarriers for therapeutic gene delivery.Asian journal of pharmaceutical sciences · 2025Review
- CT-sensitized nanoprobe for effective early diagnosis and treatment of pulmonary fibrosis.Journal of nanobiotechnology · 2025Article
- Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium.The Journal of clinical investigation · 2025Review
- From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.Pharmaceutics · 2024Review
- Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.AAPS PharmSciTech · 2024Review
- Cuproptosis-related gene CDKN2A as a molecular target for IPF diagnosis and therapeutics.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Boosting therapeutic efficacy of mesenchymal stem cells in pulmonary fibrosis: The role of genetic modification and preconditioning strategies.Iranian journal of basic medical sciences · 2023Review
- Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches.International journal of molecular sciences · 2022Review
- Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.Acta pharmaceutica Sinica. B · 2022Review
- Systematic Analysis Strategy Based on Network Pharmacology to Investigate the Potential Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition.Theranostics · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 4 institutions in 2 countries.
Jiwei HouImmunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, 210093, China.
Qijian JiDepartment of Critical Care Medicine, Xuyi People's Hospital, 28 Hongwu Road, Xuyi, 211700, Jiangsu, China.
Jie JiImmunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, 210093, China.
Shenghong JuJiangsu Key Laboratory of Molecular Imaging and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China.
Chun XuDepartment of Pathology, Medical School of Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China.
Xueqing YongDepartment of Nuclear Science & Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China.
Xiaoxuan XuJiangsu Key Laboratory of Molecular Imaging and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China.
Mohd MuddassirDepartment of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Xiang ChenImmunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, 210093, China.
Jinbing XieJiangsu Key Laboratory of Molecular Imaging and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China.
Xiaodong HanImmunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, 210093, China.
Nanjing University · CNKing Saud University · SANanjing University of Aeronautics and Astronautics · CNXuzhou No.1 People's Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsBleomycinDrug Delivery SystemsGene ExpressionHumansIdiopathic Pulmonary FibrosisImmunoglobulin Fab FragmentsLungMaleMiceMice, Inbred C57BLMicellesMolecular Targeted TherapyMyofibroblastsNADPH Oxidase 4Primary Cell CultureBleomycinImmunoglobulin Fab FragmentsMicellesNADPH Oxidase 4Nox4 protein, mouseProtein Tyrosine Phosphatase, Non-Receptor Type 13Ptpn13 protein, mouseReceptor, Platelet-Derived Growth Factor alphaRNA, Small Interferingactivationapoptosisidiopathic pulmonary fibrosis (IPF)micelle(myo)fibroblastsiRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.